Bulletin
Investor Alert

Teva Pharmaceutical Industries Ltd. ADR

NYS: TEVA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 14, 2022, 7:56 p.m.

/zigman2/quotes/205657894/composite

$

9.20

Change

+0.03 +0.33%

Volume

Volume 12,731

Quotes are delayed by 20 min

/zigman2/quotes/205657894/composite

Previous close

$ 9.20

$ 9.17

Change

-0.03 -0.33%

Day low

Day high

$9.05

$9.38

Open

52 week low

52 week high

$7.73

$13.30

Open

Company Description

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates...

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Valuation

P/E Ratio (with extraordinary items)

12.35

Price to Sales Ratio

0.58

Price to Book Ratio

1.04

Price to Cash Flow Ratio

3.71

Enterprise Value to EBITDA

6.73

Enterprise Value to Sales

2.01

Total Debt to Enterprise Value

0.74

Efficiency

Revenue/Employee

1,442,475.00

Income Per Employee

-345,488.00

Receivables Turnover

3.34

Total Asset Turnover

0.32

Liquidity

Current Ratio

0.99

Quick Ratio

0.65

Cash Ratio

0.17

Profitability

Gross Margin

46.38

Operating Margin

18.36

Pretax Margin

-26.45

Net Margin

-23.95

Return on Assets

-7.60

Return on Equity

-34.11

Return on Total Capital

7.87

Return on Invested Capital

-11.37

Capital Structure

Total Debt to Total Equity

263.30

Total Debt to Total Capital

72.47

Total Debt to Total Assets

52.13

Long-Term Debt to Equity

231.50

Long-Term Debt to Total Capital

63.72

Officers and Executives

Name Age Officer Since Title
Mr. Kåre Schultz 58 2017 President, Chief Executive Officer & Director
Dr. Eric Drapé 58 2014 Executive Vice President-Global Operations
Mr. Eli Kalif 46 2019 Chief Financial Officer & Executive Vice President
Dr. Hafrun Fridriksdottir 58 2016 Executive VP & President-Global Generics
Ms. Lori A. Queisser 59 2015 Senior Vice President & Global Compliance Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/10/2018 Bridger Management LLC
Director
250,000   Acquisition at $19.32 per share. 4,830,000
05/09/2018 Bridger Management LLC
Director
500,000   Acquisition at $19.21 per share. 9,605,000
/news/latest/company/us/teva

MarketWatch News on TEVA

  1. Jury Finds Pharmacy Chains Contributed to Opioid Crisis

    6:55 p.m. Nov. 23, 2021

    - Barron's Online

  2. Teva Pharmaceuticals plans $5 bln sustainability-linked bond

    5:08 a.m. Nov. 3, 2021

    - Ciara Linnane

  3. Teva Pharmaceutical downgraded to market perform from outperform at Raymond James

    6:58 a.m. Oct. 28, 2021

    - Tomi Kilgore

  4. Teva CEO Says He's Still Hoping For a Nationwide Opioid Settlement

    12:02 p.m. Oct. 27, 2021

    - Barron's Online

  5. Teva Earnings Miss Estimates. The Stock Is Falling.

    9:58 a.m. Oct. 27, 2021

    - Barron's Online

  6. Teva Pharmaceuticals Q3 revenue $3.887 bln vs. $3.978 bln a year ago; FactSet consensus $4.03 bln

    6:20 a.m. Oct. 27, 2021

    - Ciara Linnane

  7. CORRECTED: Teva Pharmaceuticals Q3 adj. EPS 59 cents; FactSet consensus 64 cents

    6:20 a.m. Oct. 27, 2021

    - Ciara Linnane

  8. Teva now sees full-year revenue of $16.0 bln to $16.4 bln vs. prior $16.4 bln to $16.8 bln

    6:18 a.m. July 28, 2021

    - Ciara Linnane

  9. Teva now sees full-year EPS $2.50 to $2.70

    6:19 a.m. July 28, 2021

    - Ciara Linnane

  10. Teva shares slide 3% premarket

    6:19 a.m. July 28, 2021

    - Ciara Linnane

  11. Loading more headlines...
/news/nonmarketwatch/company/us/teva

Other News on TEVA

  1. JP-Morgan-Healthcare-Conference-Presentation

    1:32 p.m. Jan. 11, 2022

    - Seeking Alpha

  2. My Nifty 50 Stock Portfolio

    4:16 p.m. Jan. 10, 2022

    - Seeking Alpha

  3. 22 Stocks That Could Double Your Money in 2022

    5:06 a.m. Jan. 3, 2022

    - Motley Fool

  4. Corrections & Amplifications

    12:01 a.m. Jan. 3, 2022

  5. Teva Found Liable for Fueling Opioid Addiction in New York

    12:48 p.m. Dec. 31, 2021

    - Scott Calvert

  6. Teva to appeal New York jury ruling in opioids trial

    1:58 p.m. Dec. 30, 2021

    - Seeking Alpha

  7. My Top 5 Portfolio Holdings for 2022

    5:51 a.m. Dec. 30, 2021

    - Motley Fool

  8. 1 Healthcare Stock to Avoid in 2022

    7:50 a.m. Dec. 29, 2021

    - Motley Fool

  9. Teva: Bracing For Next Catalyst

    4:47 p.m. Dec. 22, 2021

    - Seeking Alpha

  10. Forum Funds Buys Fiserv Inc, Tricon Residential Inc, CAE Inc

    1:38 p.m. Dec. 16, 2021

    - GuruFocus.com

  11. Why Buy Organon After Shares Fell Below $30

    7:28 a.m. Dec. 13, 2021

    - Seeking Alpha

  12. Loading more headlines...

At a Glance

Teva Pharmaceutical Industries Ltd.

5 Basel Street

Petach Tikva, HM 4951033

Phone

972 39267267

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$57.29B

Net Income

$-13.72B

Employees

39,717

/news/pressrelease/company/us/teva

Press Releases on TEVA

  1. How To Trade Teva Pharmaceutical TEVA

    5:18 p.m. Jan. 9, 2022

    - Stock Traders Daily

  2. Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference

    1:35 p.m. Jan. 4, 2022

    - BusinessWire - BZX

  3. Teva Statement Following New York Jury Ruling in Opioids Trial

    1:29 p.m. Dec. 30, 2021

    - BusinessWire - BZX

  4. Teva Pharmaceutical (TEVA) Trading Report

    3:37 a.m. Dec. 21, 2021

    - Stock Traders Daily

  5. Learn to Evaluate Teva Pharmaceutical (TEVA) using the Charts

    6:52 a.m. Dec. 11, 2021

    - Stock Traders Daily

  6. Teva Pharmaceutical TEVA Trading Report

    9:55 a.m. Dec. 1, 2021

    - Stock Traders Daily

  7. Teva Pharmaceutical TEVA Investment Analysis

    9:19 a.m. Nov. 13, 2021

    - Stock Traders Daily

  8. The $11 Trillion Healthcare Industry Is About To Change Forever

    7:02 a.m. Nov. 4, 2021

    - Financial News Media

  9. The $11 Trillion Healthcare Industry Is About To Change Forever

    7:00 a.m. Nov. 4, 2021

    - PR Newswire - PRF

  10. How To Trade Teva Pharmaceutical TEVA

    1:26 p.m. Nov. 3, 2021

    - Stock Traders Daily

  11. Loading more headlines...
Link to MarketWatch's Slice.